Clinical Trials

1,118 enrolled 40 charts

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02519348 2026-02-17

A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

433 enrolled 26 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT02516241 2026-01-28

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

1,126 enrolled 52 charts

Genitourinary

Urothelial Cancer

NCT03298451 2026-01-14

HIMALAYA

1,324 enrolled 31 charts 1 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT03703297 2025-11-21

ADRIATIC

730 enrolled 19 charts 1 FDA

Carcinoma, Lung Neoplasms, Small Cell Lung Carcinoma

NCT03043872 2025-10-21

CASPIAN

987 enrolled 42 charts 2 FDA

Phase 1/2 Active not recruiting

Small Cell Lung Carcinoma

NCT03837899 2024-10-29

Durvalumab and Tremelimumab for Pediatric Malignancies

50 enrolled 59 charts

Other hematologic neoplasm

Neoplasms, Hematologic Neoplasms

NCT03693612 2024-08-28

GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors

Phase 1/2 Completed

26 enrolled 47 charts

DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms

NCT00378482 2024-08-22

A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

DermatologicGastrointestinalGenitourinary

37 enrolled 13 charts

Carcinoma, Renal Cell, Melanoma, Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT02352948 2024-07-26

ARCTIC

Phase 3 Completed

597 enrolled 23 charts

Non - Small Cell Lung Cancer NSCLC

NCT02937818 2024-06-07

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

72 enrolled 29 charts

Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma

NCT02616185 2023-11-02

A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)

Phase 1 Terminated

91 enrolled 51 charts

Genitourinary

Prostatic Neoplasms

NCT02718911 2023-10-16

A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors

Phase 1 Completed

72 enrolled 23 charts

Other solid neoplasm

Solid Tumor

NCT03084471 2022-12-22

STRONG

Phase 3 Completed

867 enrolled 10 charts

Diabetes Mellitus, Insulin-Dependent, 12

NCT02369874 2021-02-10

EAGLE

Phase 3 Completed

736 enrolled 26 charts

Head & Neck

Head and Neck Neoplasms, Recurrence

NCT02319044 2020-09-29

Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck

267 enrolled 27 charts

Head & Neck

Head and Neck Neoplasms, Recurrence

NCT02179671 2019-08-02

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

32 enrolled 11 charts